Segment Data (Tables)

6 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Revenue from External Customers by Geographic Area

Revenues by segment, organizational unit and geographical areas for the three and six-month periods are detailed below. The Company has no material intersegment revenues.

	Three Months Ended March 31,
(Millions of dollars)	2020						2019
	United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions (a)	$	518	$	386	$	904	$	482	$	446	$	928
Medication Management Solutions (a)	449		119		568		499		118		617
Diabetes Care	142		137		278		137		133		270
Pharmaceutical Systems	91		309		400		93		273		366
Total segment revenues	$	1,200	$	951	$	2,151	$	1,211	$	969	$	2,180
Life Sciences
Integrated Diagnostic Solutions
Preanalytical Systems	$	208	$	192	$	400	$	171	$	195	$	366
Diagnostic Systems	206		228		434		180		209		389
Total Integrated Diagnostic Solutions	413		420		833		350		404		755
Biosciences	108		172		280		120		177		297
Total segment revenues	$	522	$	591	$	1,113	$	470	$	582	$	1,052
Interventional
Surgery (b)	$	249	$	63	$	312	$	242	$	66	$	308
Peripheral Intervention (b)	242		157		399		225		162		387
Urology and Critical Care (b)	202		76		279		193		75		268
Total segment revenues	$	693	$	297	$	990	$	659	$	303	$	963
Total Company revenues	$	2,415	$	1,839	$	4,253	$	2,341	$	1,854	$	4,195

(a) Prior-period amounts reflect the reclassification of U.S. revenues of $2 million associated with the movement, effective on October 1, 2019, of certain products from the Medication Delivery Solutions unit to the Medication Management Solutions unit.

(b) Prior-period amounts reflect the total reclassifications of $31 million of U.S. revenues and $13 million of international revenues associated with the movement, effective on October 1, 2019, of certain products from the Surgery unit and the Urology and Critical Care unit to the Peripheral Intervention unit.

	Six Months Ended March 31,
(Millions of dollars)	2020						2019
	United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions (a)	$	1,038	$	814	$	1,852	$	1,000	$	883	$	1,884
Medication Management Solutions (a)	912		231		1,143		1,007		236		1,242
Diabetes Care	281		266		547		282		261		544
Pharmaceutical Systems	174		525		699		161		485		646
Total segment revenues	$	2,404	$	1,836	$	4,241	$	2,450	$	1,865	$	4,316
Life Sciences
Integrated Diagnostic Solutions
Preanalytical Systems	$	410	$	388	$	798	$	371	$	387	$	758
Diagnostic Systems	390		446		835		355		416		771
Total Integrated Diagnostic Solutions	799		834		1,633		726		803		1,529
Biosciences	260		342		603		228		350		579
Total segment revenues	$	1,060	$	1,176	$	2,236	$	954	$	1,153	$	2,108
Interventional
Surgery (b)	$	505	$	133	$	638	$	488	$	130	$	618
Peripheral Intervention (b)	467		327		794		448		321		769
Urology and Critical Care (b)	409		161		570		388		158		545
Total segment revenues	$	1,381	$	621	$	2,002	$	1,323	$	609	$	1,932
Total Company revenues	$	4,845	$	3,634	$	8,479	$	4,728	$	3,628	$	8,355

(a) Prior-period amounts reflect the reclassification of U.S. revenues of $3 million associated with the movement, effective on October 1, 2019, of certain products from the Medication Delivery Solutions unit to the Medication Management Solutions unit.

(b) Prior-period amounts reflect the total reclassifications of $63 million of U.S. revenues and $28 million of international revenues associated with the movement, effective on October 1, 2019, of certain products from the Surgery unit and the Urology and Critical Care unit to the Peripheral Intervention unit.

Financial Information for Company's Segments

Segment income for the three and six-month periods was as follows:

	Three Months Ended March 31,						Six Months Ended March 31,
(Millions of dollars)	2020			2019			2020			2019
Income Before Income Taxes
Medical (a) (b)	$	443		$	599		$	1,007		$	1,265
Life Sciences (c)	285			293			646			598
Interventional	213			231			455			441
Total Segment Operating Income	941			1,123			2,109			2,303
Acquisitions and other restructurings	(75		)	(101		)	(161		)	(191		)
Net interest expense	(132		)	(153		)	(266		)	(336		)
Other unallocated items (d)	(534		)	(866		)	(1,087		)	(1,058		)
Total Income Before Income Taxes	$	200		$	3		$	594		$	718

(a) The amounts for the three and six months ended March 31, 2020 include a probable estimate of future costs within the Medication Management Solutions unit associated with remediation efforts related to Alaris^TM infusion pumps of $199 million and $258 million, respectively, which were recorded to Cost of products sold. Based on the course of remediation efforts, it is possible that the estimate of future costs could increase over time. 

(b) The amounts for the three and six-month periods in 2019 included $65 million of estimated remediation costs recorded to Other operating expense, net relating to a recall of a product component, which generally pre-dated the Company's acquisition of CareFusion in fiscal year 2015, within the Medication Management Solutions unit's infusion systems platform.

(c) The amounts for the three and six-month periods in 2020 include a charge of $39 million recorded to Cost of products sold to write down the carrying value of certain intangible assets in the Biosciences unit.

(d)

Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The amounts for the three and six-month periods in 2019 include a pre-tax charge of $331 million related to certain product liability matters, which is further discussed in Note 5. In addition, the amount for the six months ended March 31, 2019 included the pre-tax gain recognized on the Company's sale of its Advanced Bioprocessing business of approximately $335 million, which is further discussed in Note 9.